Integrated fibrinogen-platelet score (F-P Score) in ovarian carcinoma: diagnostic value for differentiating early and advanced stage
Keywords:
ovarian cancer, CA-125, fibrinogen, platelets, F-P Score, ROC analysisAbstract
Introduction: Ovarian carcinoma is often diagnosed at an advanced stage due to the absence of early symptoms. While the tumor marker CA-125 is highly sensitive, it has limited specificity. Modern research demonstrates that tumor-induced systemic inflammation and hypercoagulation play a key role in tumor progression. Objective: The study aims to evaluate the correlation between preoperative CA-125 levels and the combined Fibrinogen-Platelet Score (F-P Score) in patients at different stages of ovarian carcinoma, and to analyze their potential to differentiate between early and advanced stages of the disease. Material and Methods: A retrospective study was conducted involving 60 patients with histologically confirmed ovarian carcinoma (Stage I, n = 19; Stage II, n = 19; Stage III, n = 22). Patients in Stage IV were not included in the study. Serum CA-125, plasma fibrinogen, and platelet count (PLT) were examined. The F-P Score was calculated (0, 1, or 2 points based on the reference ranges for fibrinogen and PLT). Statistical analysis included ANOVA, the Kruskal-Wallis test, the χ2 (Chi-square) test, and ROC analysis. Results: A statistically significant increase in all examined parameters was observed alongside the advancement of the clinical stage (p < 0.001). In stage I, 100% of the patients had an F-P Score of 0, whereas in Stage III, 54.5% reached the maximum score of 2 points. ROC analysis showed that the individual assessment of fibrinogen (AUC = 0.927) and platelets (AUC = 0.754) was inferior in diagnostic accuracy to the combined F-P Score, which demonstrated the highest area under the curve (AUC = 0.932; 95% CI: 0.869-0.995). Conclusion: While CA-125 remains a highly sensitive marker for the presence of a tumor process, the F-P Score is a more reliable marker for preoperative staging and assessment of invasiveness. Its inclusion in clinical practice may improve patient stratification and the prediction of the tumor’s biological behavior.
References
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Erratum in: CA Cancer J Clin. 2024 MarApr;74(2):203. doi: 10.3322/caac.21830
Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2
Bottoni P, Scatena R. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:229-44. doi: 10.1007/978-94-017-7215-0_14
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205
Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 10.1056/NEJMoa1110352. Erratum in: N Engl J Med. 2012 Nov;367(18):1768.
Seebacher V, Polterauer S, Grimm C, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010 Mar 16;102(6):952-6. doi: 10.1038/sj.bjc.6605547
Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178-85. doi: 10.1182/blood-2004-06-2272
Qiu J, Yu Y, Fu Y, et al. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 2012;38(4):651-7. doi: 10.1111/j.1447-0756.2011.01780.x
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. doi: 10.1016/s0092-8674(00)81683-9
Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274-81. doi: 10.1111/j.1525-1438.2005.00441.x
Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008 Feb;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017
Polterauer S, Grimm C, Seebacher V, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist. 2009 Oct;14(10):979-85. doi: 10.1634/theoncologist.2009-0079
Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002 Sep;22(9):913-22. doi: 10.1089/10799900260286623
Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012 Dec;2(12):1091-9. doi: 10.1158/2159-8290.CD-12-0329
Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012 Jun 15;130(12):2747-60. doi: 10.1002/ijc.27441
Ferroni P, Spila A, Martini F, et al. Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology. 2005;69(2):145-53. doi: 10.1159/000087838
Hufnagel DH, Cozzi GD, Crispens MA, et al. Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature. Int J Mol Sci. 2020 Oct 31;21(21):8169. doi: 10.3390/ijms21218169
He Q, Li Y, Zhou X, et al. The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs. J Int Med Res. 2021 Apr;49(4):3000605211004021. doi: 10.1177/03000605211004021
Man YN, Wang YN, Hao J, et al. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer. 2015 Jan;25(1):24-32. doi: 10.1097/IGC.0000000000000303
Downloads
Published
Issue
Section
License
Copyright (c) 2026 V. Racheva, E. Petkovа, M. Nistorova, T. Velkovska (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
